Growth Metrics

Novartis Ag (NVS) Net Cash Flow Growth (1y) (2010 - 2025)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (1y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -568.73%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -85.99%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 1,265.92%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -95.55%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 191.97%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 103.60%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 42.41%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -227.06%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 60.53%
Sep 30, 2025 -13.76%
Jun 30, 2025 48.30%
Dec 31, 2024 -189.94%
Sep 30, 2024 9.13%
Jun 30, 2024 -37.52%
Dec 31, 2023 192.22%
Jun 30, 2023 89.05%
Dec 31, 2022 -18,460.00%
Jun 30, 2022 -888.76%
Dec 31, 2021 -99.26%
Sep 30, 2021 420.63%
Jun 30, 2021 -4.52%
Dec 31, 2020 1,392.45%
Jun 30, 2020 -48.22%
Dec 31, 2019 109.14%
Jun 30, 2019 -61.27%
Dec 31, 2018 -249.50%
Sep 30, 2018 -29.34%
Jun 30, 2018 2,791.42%
Dec 31, 2017 -17.59%
Sep 30, 2017 33.56%
Jun 30, 2017 139.29%
Mar 31, 2017 31.21%
Sep 30, 2016 -68.19%
Sep 30, 2015 -1,135,185,285.19%
Dec 31, 2014 -1,099.35%
Sep 30, 2014 107.17%
Jun 30, 2014 -29.50%
Jun 30, 2013 17.01%
Mar 31, 2013 256.40%
Jun 30, 2012 -757.27%
Mar 31, 2012 -11,225.00%
Dec 31, 2011 -314.03%
Jun 30, 2011 -88.42%
Mar 31, 2011 -99.82%
Dec 31, 2010 -100.00%
Jun 30, 2010 933.33%
Mar 31, 2010 601.83%